Researchers have developed a novel combination therapy using an anticancer agent, mitoxantrone (MTX), together with an antibiotic, vancomycin, for treating bacteria that are resistant to the vancomycin, which is also known as vancomycin-resistant Enterococcus faecalis (VRE). The therapy uniquely targets both VRE and the host, stimulating the host immune system to more effectively clear bacterial infections and accelerate infected wound healing.
from Medical Xpress - latest medical and health news stories https://ift.tt/X3ZcqM6
